Irinotecan and radiosensitization in rectal cancer

Anti-Cancer Drugs

Volumn 22, Issue 4, 2011, Pages 324-329

  Illum, Henrik ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Abdominal perineal resection; irinotecan; low anterior resection; pCR; radiation; rectal cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; CAMPTOTHECIN; CAPECITABINE; DNA TOPOISOMERASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ABDOMINAL PAIN; ANASTOMOSIS LEAKAGE; ASTHENIA; CANCER CELL CULTURE; COLORECTAL CANCER; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; HUMANS; META-ANALYSIS AS TOPIC; NEOADJUVANT THERAPY; RADIATION-SENSITIZING AGENTS; RECTAL NEOPLASMS;

EID: 79952991661     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283425c14     Document Type: Review

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-249.
2. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
3. Rodel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-8696. (Pubitemid 46211512)
4. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992;19:663-669. (Pubitemid 23004843)
5. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. JNCI 1993;85:271-291. (Pubitemid 23068801)
6. Burris HA, Fields SM. Topoisomerase I inhibitors. Hematol Oncol Clin North Am 1994;8:333-355.
7. Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Huntington) 1999;13(10 Suppl 5):39-46.
8. Slichenmyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol 1990;30:770-788. (Pubitemid 20334336)
9. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochem Biophys Acta 1998;1400:107-119. (Pubitemid 28475098)
10. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-4191.
11. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-814. (Pubitemid 46606439)
12. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckardt JR, Tristan-Morales M, et al. Phase I and pharmacokinetics trial of weekly CPT-11. J Clin Oncol 1993;11:2194-2204.
13. Product info for Camptosar inj. Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical, Co., LTD, Japan Revised August 2010.
14. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-259. (Pubitemid 27429892)
15. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992;50:604-610.
16. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP- glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-1175.
17. Black M, Billing BH. Hepatic bilirubin UDP-glucuronyl transferase activity in liver disease and Gilbert's syndrome. N Engl J Med 1969;280:1266-1271.
18. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388. (Pubitemid 41103619)
19. *28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061-3068. (Pubitemid 46638941)
20. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007;13:3269-3275. (Pubitemid 46944912)
21. *28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008;112:1932-1940.
22. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594-2600. (Pubitemid 47041233)
23. *28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-1295. (Pubitemid 47394168)
24. Invader UGT1A1 Molecular Assay for Irinotecan Toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar). Med Lett Drugs Ther 2006;48:39-40.
25. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009;27:2457-2465.
26. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-2614.
27. Van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, Van Schaik RH, de Jonge MJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2719-2726. (Pubitemid 47123179)
28. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008;83:601-606. (Pubitemid 351417055)
29. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008;34:656-669.
30. Chen AY, Okunieff P, Pommier Y, Mitchell JB. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 1997;57:1529-1536. (Pubitemid 27175571)
31. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys 1996;36:369-376. (Pubitemid 26359463)
32. Amorino GP, Hercules SK, Mohr PJ, Pyo H, Choy H. Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20 (S) - camptothecin) as a radiation enhancer. Int J Radiat Oncol Biol Phys 2000;47:503-509. (Pubitemid 30236394)
33. Omura M, Torigoe S, Kubota N. SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Rad Oncol 1997;43:197-201. (Pubitemid 27261591)
34. Tamura K, Takada M, Kawase I, Tada T, Kudoh S, Okishio K, et al. Enhancement of tumor radioresponse by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 1997;88:218-223. (Pubitemid 27129651)
35. Voelter V, Zouhair A, Vuilleumier H, Matter M, Bouzourene H, Leyvraz S, et al. CPT-11 and concomitant hyperfractionated-accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. Br J Cancer 2006;95:710-716. (Pubitemid 44373486)
36. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003;55:132-137. (Pubitemid 36020352)
37. Klautke G, Küchenmeister U, Foitzik T, Ludwig K, Prall F, Klar E, et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006;94:976-981.
38. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Müldner A, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005;23:1350-1357.
39. Navarro M, Dotor E, Rivera F, Sánchez-Rovira P, Vega-Villegas ME, Cervantes A, et al. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006;66:201-205. (Pubitemid 44175647)
40. Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 2007;96:551-558.
41. Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007;96:912-917. (Pubitemid 46452282)
42. Gollins SW, Myint S, Susnerwala S, Haylock B, Wise M, Topham C, et al. Preoperative down staging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). Br J Cancer 2009;101:924-934.
43. Hong YS, Kim DY, Lim SB, Choi HS, Jeong SY, Jeong JY, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
44. Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, et al. Randomized phase II study of neoadjuvant-combined modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006;24:650-655. (Pubitemid 46630429)
45. Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, et al. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Radiother Oncol 2010;95:303-307.
46. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009;74:1487-1493.
47. Voelter V, Stupp R, Matter M, Gillet M, Bouzourene H, Leyvraz S, et al. Preoperative hyperfractionated-accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol Biol Phys 2003;56:1288-1294. (Pubitemid 36842880)
48. Sato T, Kokuba Y, Koizumi W, Ozawa H, Nakamura T, Ihara A, et al. Irinotecan and S-1 neoadjuvant chemoradiation therapy in patients with advanced rectal cancer. Hepatogastroenterology 2007;54:1391-1393. (Pubitemid 47203433)
49. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009;20:519-524.
50. Ziras N, Tsoutsou P, Koliarakis N, Magdalinos N, Sarris G, Potamianou A, et al. Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5-fluorouracil and folinic acid in locally advanced rectal cancer. J BUON 2004;9:255-261. (Pubitemid 40360800)
51. Yasui M, Ikeda M, Sekimoto M, Yamamoto H, Takemasa I, Ueda T, et al. Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer. World J Surg Oncol 2006;4:83.